Escalating doses and improving outcomes in cutaneous T-cell lymphomas
Highlights from EHA 2016 press briefings: POLLUX and EURO-SKI trials and BiTE antibodies
Combining FLT3 and SYK inhibition for AML
Re-treatment of patients refractory to daratumumab
Heinz Ludwig et al.
The current status of CLL treatment